HC Wainwright Forecasts Agenus' Q3 Earnings (NASDAQ:AGEN)

Agenus Inc. (NASDAQ:AGEN - Free Report) - Stock analysts at HC Wainwright raised their Q3 2025 EPS estimates for shares of Agenus in a report issued on Wednesday, June 4th. HC Wainwright analyst E. Bodnar now forecasts that the biotechnology company will earn $0.25 per share for the quarter, up from their previous estimate of ($0.36). HC Wainwright currently has a "Buy" rating and a $25.00 price target on the stock. The consensus estimate for Agenus' current full-year earnings is ($12.55) per share. HC Wainwright also issued estimates for Agenus' Q4 2025 earnings at $0.41 EPS, FY2026 earnings at $1.16 EPS, FY2027 earnings at ($1.37) EPS, FY2028 earnings at ($2.36) EPS and FY2029 earnings at ($0.67) EPS.

Agenus (NASDAQ:AGEN - Get Free Report) last released its quarterly earnings data on Monday, May 12th. The biotechnology company reported ($1.03) earnings per share for the quarter, beating the consensus estimate of ($1.61) by $0.58. The company had revenue of $24.07 million during the quarter, compared to analyst estimates of $26.38 million.

A number of other brokerages have also recently weighed in on AGEN. Robert W. Baird lifted their price target on shares of Agenus from $4.00 to $6.00 and gave the company a "neutral" rating in a research report on Wednesday. Wall Street Zen upgraded shares of Agenus from a "strong sell" rating to a "hold" rating in a report on Thursday, May 22nd. Finally, B. Riley restated a "buy" rating on shares of Agenus in a report on Monday, April 21st. Five investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Hold" and a consensus target price of $14.00.

Agenus Stock Performance

Shares of AGEN opened at $5.16 on Friday. The firm's 50 day moving average price is $2.89 and its 200 day moving average price is $2.94. Agenus has a twelve month low of $1.38 and a twelve month high of $18.74. The firm has a market cap of $141.47 million, a PE ratio of -0.46 and a beta of 1.48.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. Barclays PLC increased its stake in Agenus by 17.7% in the fourth quarter. Barclays PLC now owns 32,737 shares of the biotechnology company's stock valued at $90,000 after acquiring an additional 4,924 shares during the period. Apollon Wealth Management LLC grew its stake in shares of Agenus by 25.0% in the 1st quarter. Apollon Wealth Management LLC now owns 25,007 shares of the biotechnology company's stock valued at $38,000 after purchasing an additional 5,000 shares during the period. Corton Capital Inc. acquired a new position in shares of Agenus in the 4th quarter worth approximately $36,000. Charles Schwab Investment Management Inc. raised its holdings in shares of Agenus by 32.8% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 63,685 shares of the biotechnology company's stock worth $96,000 after buying an additional 15,731 shares in the last quarter. Finally, Virtu Financial LLC bought a new position in shares of Agenus during the 4th quarter worth approximately $51,000. 61.46% of the stock is currently owned by institutional investors and hedge funds.

Agenus Company Profile

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.